Your browser doesn't support javascript.
loading
A third of the radiotracer dose: two decades of progress in pediatric [18F]fluorodeoxyglucose PET/CT and PET/MR imaging.
Waelti, Stephan; Skawran, Stephan; Sartoretti, Thomas; Schwyzer, Moritz; Gennari, Antonio G; Mader, Cäcilia; Treyer, Valerie; Kellenberger, Christian J; Burger, Irene A; Hany, Thomas; Maurer, Alexander; Huellner, Martin W; Messerli, Michael.
Afiliación
  • Waelti S; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.
  • Skawran S; University of Zurich, Zurich, Switzerland.
  • Sartoretti T; Department of Radiology and Nuclear Medicine, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.
  • Schwyzer M; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.
  • Gennari AG; University of Zurich, Zurich, Switzerland.
  • Mader C; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.
  • Treyer V; University of Zurich, Zurich, Switzerland.
  • Kellenberger CJ; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.
  • Burger IA; University of Zurich, Zurich, Switzerland.
  • Hany T; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.
  • Maurer A; University of Zurich, Zurich, Switzerland.
  • Huellner MW; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.
  • Messerli M; University of Zurich, Zurich, Switzerland.
Eur Radiol ; 2023 Oct 19.
Article en En | MEDLINE | ID: mdl-37855853
ABSTRACT

OBJECTIVES:

To assess the evolution of administered radiotracer activity for F-18-fluorodeoxyglucose (18F-FDG) PET/CT or PET/MR in pediatric patients (0-16 years) between years 2000 and 2021.

METHODS:

Pediatric patients (≤ 16 years) referred for 18F-FDG PET/CT or PET/MR imaging of the body during 2000 and 2021 were retrospectively included. The amount of administered radiotracer activity in megabecquerel (MBq) was recorded, and signal-to-noise ratio (SNR) was measured in the right liver lobe with a 4 cm3 volume of interest as an indicator for objective image quality. Descriptive statistics were computed.

RESULTS:

Two hundred forty-three children and adolescents underwent a total of 466 examinations. The median injected 18F-FDG activity in MBq decreased significantly from 296 MBq in 2000-2005 to 100 MBq in 2016-2021 (p < 0.001), equaling approximately one-third of the initial amount. The median SNR ratio was stable during all years with 11.7 (interquartile range [IQR] 10.7-12.9, p = 0.133).

CONCLUSIONS:

Children have benefited from a massive reduction in the administered 18F-FDG dose over the past 20 years without compromising objective image quality. CLINICAL RELEVANCE STATEMENT Radiotracer dose was reduced considerably over the past two decades of pediatric F-18-fluorodeoxyglucose PET/CT and PET/MR imaging highlighting the success of technical innovations in pediatric PET imaging. KEY POINTS • The evolution of administered radiotracer activity for F-18-fluorodeoxyglucose (18F-FDG) PET/CT or PET/MR in pediatric patients (0-16 years) between 2000 and 2021 was assessed. • The injected tracer activity decreased by 66% during the study period from 296 megabecquerel (MBq) to 100 MBq (p < 0.001). • The continuous implementation of technical innovations in pediatric hybrid 18F-FDG PET has led to a steady decrease in the amount of applied radiotracer, which is particularly beneficial for children who are more sensitive to radiation.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Eur Radiol Asunto de la revista: RADIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Suiza

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Eur Radiol Asunto de la revista: RADIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Suiza